SAFETY PROFILE of JAK INHIBITORS in REAL WORLD from A SINGLE CENTER COHORT
Annals of the Rheumatic Diseases
; 81:1286, 2022.
Article
in English
| EMBASE | ID: covidwho-2009174
ABSTRACT
Background:
Recent published data have emerged some concerns about safety of Janus kinase (JAK) inhibitors and FDA have established prescribing restrictions.Objectives:
The aim of this study was to analyze the safety profile of current approved JAK inhibitors in Europe with data from a Real World cohort.Methods:
A single center observational study was performed including patients who had initiated treatment with Tofacitinib, Baricitinib or Upadacitinib from September, 2017 to January, 2022. Demographic, clinical, laboratory and safety variables were collected from baseline and at months 1, 3, 6 and every six months. Safety data was collected including any adverse event (AE) due to any cause. An AE was considered serious if it was life-threatening or result in hospitaliza-tion, disability or in death. All AE and SAE were expressed adjusted by exposure (E/100 PY).Results:
A total of 194 patients were included whom baseline demographic and disease characteristics are exposed in Table 1. Drug exposure was 265.5 patient-years. Overall, 214 AE were detected being mild upper tract respiratory infection the most frequently registered (15.82 E/100PY) followed by Urinary tract Infection accounting 7.16 E/100PY. 10 Serious Infections were detected in 10 patients of which 5 were pneumonia (1.88 E/100PY), 1 cellulitis (0.38 E/100PY) and 2 COVID-19 (0.76 E/100PY). 12 herpetic infection were detected in 9 patients (4.52 E/100PY) of which 7 were caused by herpes zoster (2.64 E/100PY) and 5 by herpes simplex (1.88 E/100PY) 3 cases were mono-metameric and 4 multi-metameric. Moreover, 2 patient developed postherpetic neuralgia. A patient with RA developed Miliary Tuberculosis (0.38 E/100PY) with a negative IGRA test prior to the JAKi. A patient with RA suffered a Myocardial Infarction (0.38 E/100PY). 7 RA patients developed malignancy (2.64 E/100PY), one with oral squamous cell carcinoma, two Bowen carcinoma, one breast cancer, 2 basal cell carcinoma and a colorectal metastatic cancer. Not a single case of thromboembolic event nor Hepatitis B Virus reactivation were registered. 2 patients died, one with cancer and the other suffered a severe COVID-19 (unvaccinated).Conclusion:
In this updated analysis of 194 patients treated with JAKi, the three approved JAKi showed a safety profile consistent with data from RCT. The patients under JAK therapy should be carefully evaluated on their follow-up.
baricitinib; endogenous compound; Janus kinase; Janus kinase inhibitor; tofacitinib; upadacitinib; adult; basal cell carcinoma; breast cancer; cancer patient; cellulitis; clinical laboratory; conference abstract; coronavirus disease 2019; demography; disability; drug exposure; drug safety; Europe; female; follow up; heart infarction; Hepatitis B virus; herpes simplex; herpes zoster; human; major clinical study; metastasis; miliary tuberculosis; mouth squamous cell carcinoma; nonhuman; observational study; pneumonia; postherpetic neuralgia; respiratory tract infection; thromboembolism; urinary tract infection; virus reactivation
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS